Elie Haddad, MD
Cardiovascular Disease · Miami, FLNPI 1740242361
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 243 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by Impulse Dynamics (USA) Inc. at 24.6% of the total. Reporting peaked in 2022 at $2,727 and has fallen 66.2% since, to $921 in 2025.
Across 243 payments — averaging $45.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Impulse Dynamics (USA) Inc.$3K
- Abbott$2K
- Biotronik Inc.$2K
- Medtronic$1K
- AstraZeneca$483
- Lilly USA, LLC$477
- plus $2K from 27 others
Across 38 payments — averaging $1269.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Impulse Dynamics (USA) Inc.$45K
- Biotronik Inc.$3K
What the payments were for
- Consulting fees$4004%
- Food & beverage$10,69896%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Impulse Dynamics (USA) Inc. | 29 | $2,729 |
| Abbott | 33 | $2,123 |
| Biotronik Inc. | 21 | $1,656 |
| Medtronic(2 entities) | 28 | $1,227 |
| AstraZeneca(2 entities) | 13 | $483 |
| Lilly USA, LLC | 25 | $477 |
| Mallinckrodt Hospital Products Inc. | 11 | $277 |
| Amgen | 14 | $270 |
| Johnson & Johnson | 8 | $228 |
| UCB, Inc. | 11 | $221 |
| Novartis | 7 | $216 |
| Lexicon Pharmaceuticals, Inc. | 3 | $169 |
| Philips North America LLC | 1 | $130 |
| E.r. Squibb & Sons, L.L.C. | 7 | $126 |
| Boston Scientific | 1 | $101 |
| Aurinia Pharma U.S., Inc. | 4 | $90 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $74 |
| Sobi, Inc | 3 | $61 |
| Boehringer Ingelheim | 2 | $49 |
| Alvogen Inc | 2 | $48 |
| Pfizer | 2 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Novo Nordisk | 2 | $41 |
| ANI Pharmaceuticals, Inc. | 1 | $34 |
| Radius Health, Inc. | 1 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| GSK | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Bristol Myers Squibb | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$3,365
- GALLANT$301
- Confirm Rx$251
- FARXIGA$250
- Micra$229
- EnSite Precision Cardiac Mapping System$153
- Reveal LINQ$153
- OPTIMIZER SMART SYSTEM$151
- Cobalt$146
- BioMonitor$140
- (9124) LM Undivided$130
- ENTRESTO$125
- Acticor 7 VR-T DX$123
- Inpefa$122
- Quadra Allure MP RF CRT Pacemkr$117
- XARELTO$106
- Watchman$101
How this compares
$11,105 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 617 | $538,740 |
| EntrestoSacubitril/Valsartan | 298 | $266,700 |
| JardianceEmpagliflozin | 142 | $134,501 |
| XareltoRivaroxaban | 154 | $117,520 |
| FarxigaDapagliflozin Propanediol | 73 | $65,765 |
| MultaqDronedarone Hcl | 45 | $43,850 |
| Repatha SureclickEvolocumab | 38 | $23,334 |
| OzempicSemaglutide | 24 | $22,336 |
| Tadalafil | 13 | $20,726 |
| MounjaroTirzepatide | 18 | $19,212 |
| BrilintaTicagrelor | 28 | $17,564 |
| VascepaIcosapent Ethyl | 32 | $13,732 |
| EdarbiAzilsartan Medoxomil | 25 | $8,296 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 24 | $8,151 |
| Flecainide Acetate | 203 | $7,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $45 | $538,740617 claims |
| NovartisEntresto | $216 | $266,700298 claims |
| Boehringer IngelheimJardiance, Pradaxa | $49 | $140,207159 claims |
| Johnson & JohnsonXarelto | $228 | $117,520154 claims |
| AstraZenecaFarxiga, Brilinta | $483 | $83,329101 claims |
| Sanofi-aventis U.S. LLCMultaq | $45 | $43,85045 claims |
| Novo NordiskOzempic | $41 | $22,33624 claims |
| Lilly USA, LLCMounjaro | $477 | $19,21218 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $26 | $16,44749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Miami
- Theodore FeldmanMiami$637K
- Elliott EliasMiami$497K
- Ian del Conde PozziMiami$243K
- Jonathan FialkowMiami$153K
- Bernard AshbyMiami$115K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.